At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 114 enrolled
Drug / intervention
Mogamulizumab + Nivolumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Mogamulizumab + Nivolumab for Solid Tumor and 4 related conditions. Completed, enrolled 114 participants across 15 sites.
Detailed Summary
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma, HCC
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedMar 2016
Primary CompletionAug 2018
Study CompletionOct 2018
TodayJul 2026
First PostedMar 10, 2016
Enrollment StartFeb 1, 2016
Primary CompletionAug 22, 2018
Study CompletionOct 10, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.3 years ago
Interventions
Mogamulizumab + Nivolumabbiological
i.v. administration